About Shenzhen Kangtai Biological Products Company

Founded in 1992, the company has grown into an innovative biopharmaceutical enterprise with robust R&D capabilities, a diversified product portfolio, leading industry scale, and significant internationalization progress. Adhering to a dual strategy of "bringing in" and "going out," the company is steadily advancing its global expansion. Its core business encompasses the research, development, manufacturing, and marketing of human vaccines. Key products include recombinant hepatitis B vaccine (Saccharomyces cerevisiae), 13-valent pneumococcal polysaccharide conjugate vaccine, acellular pertussis–diphtheria–tetanus–Haemophilus influenzae type b combination vaccine, lyophilized human rabies vaccine (human diploid cell‑derived), 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b conjugate vaccine, measles–rubella combined attenuated live vaccine, adsorbed acellular pertussis–diphtheria–tetanus combination vaccine, varicella attenuated live vaccine, Sabin‑strain inactivated poliovirus vaccine (Vero cell‑derived), novel coronavirus inactivated vaccine (Vero cell‑derived), recombinant novel coronavirus vaccine (Y25 adenoviral vector), quadrivalent inactivated influenza vaccine (for individuals aged 3 years and older), and adsorbed tetanus vaccine. The company has been recognized with numerous honors, including Guangdong Province's Innovative Enterprise designation, Guangdong Province High‑Tech Product Certification, National Torch Program Key High‑Tech Enterprise Certificate, Guangdong Province Young Leading Enterprise Award, and Shenzhen Science and Technology Progress Award, among others.